AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

AstraZeneca shares are forming a lengthy consolidation with a buy point at 87.67, but remain below their 200-day moving average, MarketSurge shows. Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor. Among many others, ...

A host of corporate developments—from regulatory actions and major contracts to earnings, acquisitions, and management ...

The FTSE 100 and European stocks were jittery on Friday, moving lower as US markets were closed for 4 July, while investors look to movement in US tax and tariff policy for clues ...

The FTSE 100 index closed up 48.51 points, 0.6%, at 8,823.20. The FTSE 250 jumped 250.09 points, 1.2%, at 21,702.58, and the ...

The team at Surbana Jurong expects Singapore's private sector developers to adopt a more cautious approach, particularly if ...

The FTSE 100 and sterling rallied, while the bond market calmed on Thursday as Keir Starmer supported his chancellor, reassuring markets that a change at the Treasury wasn't on the cards. The FTSE 100 ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...